Masaki Daini

Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects.

H. Oki, S. Iwasaki, S. Morimoto, 2022, European journal of medicinal chemistry.

Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore.

H. Oki, T. Ohashi, Yuta Tanaka, 2022, Journal of medicinal chemistry.

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models

H. Oki, S. Igaki, Ryuji Yamada, 2021, Science Advances.

Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome

H. Bjornsson, E. Pich, J. Dunlop, 2020, bioRxiv.

Design and synthesis of 6-methylpyridin-2-one derivatives as novel and potent GluN2A positive allosteric modulators for the treatment of cognitive impairment.

Tomoaki Hasui, M. Corsi, H. Kakei, 2022, Bioorganic & medicinal chemistry.